# Factor VIIa in Acute Intracerebral Haemorrhage

> **NCT00266006** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 90 (actual)

## Conditions studied

- Acquired Bleeding Disorder
- Intracerebral Haemorrhage

## Interventions

- **DRUG:** eptacog alfa (activated)

## Key facts

- **NCT ID:** NCT00266006
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00266006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00266006, "Factor VIIa in Acute Intracerebral Haemorrhage". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00266006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*